VBL Therapeutics to Present New Data on Its MOSPD2 Bispecific Antibody Program for Solid Tumors in Late Breaking Research Ses...
May 18 2020 - 7:00AM
VBL Therapeutics (Nasdaq: VBLT) announced today that new data
suggesting the potential of its proprietary bi-specific antibodies
for immune-mediated targeting of solid tumors will be presented at
the Annual American Association for Cancer Research (AACR) Virtual
Annual Meeting II, to be held June 22–24, 2020. VBL's data show
that MOSPD2 bi-specific antibodies induce T-cell activation and
significantly extend the survival of mice carrying established
metastatic cervical cancer, with no evidence of toxicity.
VBL's research has identified MOSPD2 as a protein involved in
cell motility, whose expression is highly elevated in various solid
tumors. The proprietary bi-specific antibodies developed by VBL
have two separate arms – one arm binds to MOSPD2 on tumor cells and
the second recruits host T-cells that attack the tumor. The new
data to be presented at AACR highlight the potential of bi-specific
mediated immuno-oncology investigational therapy for the treatment
of various MOSPD2-expressing solid tumors.
Details for the AACR 2020 Virtual Meeting II
presentations are as follows :
- Permanent Abstract Number: LB-086
Title: CD3 MOSPD2 bi-specific antibody
significantly prolongs survival in a model of metastatic human
cervical cancer without any evidence of
toxicityAuthors: Yacov et al. Session
Type: Poster Session Session Category:
Immunology Session Title: Late-Breaking Research:
Immunology 1
- Permanent Abstract Number: 5592
Title: MOSPD2 a novel target for bi-specific
antibody mediated solid tumor cells immune
deathAuthors: Salem et al.Session
Type: Poster Session Session Category:
Immunology Session Title: Inflammation, Immunity,
and Cancer / Modifiers of the Tumor Microenvironment 2
VBL's presentations will be available on the AACR e-poster
website on June 22, 2020.
About VBL's VB-600 PlatformVBL is conducting
two parallel drug development programs that are exploring the
potential of MOSPD2 (motile sperm domain-containing protein 2), a
protein that VBL has identified as a key regulator of cell
motility, as a therapeutic target for inflammatory diseases and
cancer. Our VB-600 platform comprises classical anti-MOSPD2
investigational monoclonal antibodies for inflammatory indications,
as well as bi-specific antibody candidates for oncology.
About VBLVascular Biogenics Ltd., operating as
VBL Therapeutics, is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
first-in-class treatments for cancer. VBL’s lead oncology product
candidate, ofranergene obadenovec (VB-111), is a first-in-class,
targeted anti-cancer gene-therapy agent that is being developed to
treat a wide range of solid tumors. It is conveniently administered
as an IV infusion once every two months. It has been observed to be
well-tolerated in >300 cancer patients and demonstrated activity
signals in a VBL-sponsored “all comers” phase 1 trial as well as in
three VBL-sponsored tumor-specific phase 2 studies. Ofranergene
obadenovec is currently being studied in a VBL-sponsored phase 3
potential registration trial for platinum-resistant ovarian
cancer.
Forward Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “will,”
“would” and similar expressions. These forward-looking statements
may include, but are not limited to, statements regarding our
programs, including MOSPD2, including their clinical development,
therapeutic potential and clinical results and the impact of the
COVID-19 pandemic on our business, operations, clinical trials,
supply chain, strategy, goals and anticipated timelines and
clinical results. These forward-looking statements are not promises
or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ
materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the
risk that historical clinical trial results may not be predictive
of future trial results, that our financial resources do not last
for as long as anticipated, and that we may not realize the
expected benefits of our intellectual property protection. A
further list and description of these risks, uncertainties and
other risks can be found in our regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2019, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024